In preclinical models, STK11 inactivation often led to cancer progression and metastasis and was associated with indolent tumor immune microenvironment, exhibiting as a reduced density of infiltrating cytotoxic CD8+ T lymphocytes, decreased PD-(L)1 expression and a neutrophil-rich tumor microenvironment (7). Here, CD8A is linked to cancer.